FDA Grants Priority Review to Taletrectinib in ROS1+ Advanced NSCLC - OncLive
The FDA granted priority review to taletrectinib for ROS1-positive advanced NSCLC, supported by phase 2 TRUST trials showing ORR of 88.8% in TKI-naive patients and 55.8% in previously treated patients. The FDA target action date is June 23, 2025.
Related Clinical Trials
Highlighted Terms
Related News
FDA Grants Priority Review to Taletrectinib in ROS1+ Advanced NSCLC - OncLive
The FDA granted priority review to taletrectinib for ROS1-positive advanced NSCLC, supported by phase 2 TRUST trials showing ORR of 88.8% in TKI-naive patients and 55.8% in previously treated patients. The FDA target action date is June 23, 2025.